World Library  

Add to Book Shelf
Flag as Inappropriate
Email this Book

Plos One : Efficacy and Safety of Telavancin in Clinical Trials ; a Systematic Review and Meta-analysis, Volume 7

By Spellberg, Brad

Click here to view

Book Id: WPLBN0003936900
Format Type: PDF eBook :
File Size:
Reproduction Date: 2015

Title: Plos One : Efficacy and Safety of Telavancin in Clinical Trials ; a Systematic Review and Meta-analysis, Volume 7  
Author: Spellberg, Brad
Volume: Volume 7
Language: English
Subject: Journals, Science, Medical Science
Collections: Periodicals: Journal and Magazine Collection
Publication Date:
Publisher: Plos


APA MLA Chicago

Spellberg, B. (n.d.). Plos One : Efficacy and Safety of Telavancin in Clinical Trials ; a Systematic Review and Meta-analysis, Volume 7. Retrieved from

Description : Introduction : The epidemiology and antibiotic resistance of Staphylococcus aureus have evolved, underscoring the need for novel antibiotics, particularly against methicillin-resistant S. aureus (MRSA). Telavancin is a bactericidal lipoglycopeptide with potent activity against Gram-positive pathogens. Objective : To systematically review and synthesize the available evidence from randomized controlled trials (RCTs) evaluating telavancin in the treatment of patients with infections due to Gram-positive organisms with the methodology of meta-analysis. Results : Six RCTs comparing telavancin with vancomycin were included: 4 (2229 patients) referred to complicated skin and soft tissue infections (cSSTIs) and 2 (1503 patients) to hospital-acquired pneumonia (HAP). Regarding cSSTIs, telavancin and vancomycin showed comparable efficacy in clinically evaluable patients (odds ratio [OR] = 1.10 [95% confidence intervals: 0.82–1.48]). Among patients with MRSA infection, telavancin showed higher eradication rates (OR = 1.71 [1.08–2.70]) and a trend towards better clinical response (OR = 1.55 [0.93–2.58]). Regarding HAP, telavancin was non-inferior to vancomycin in terms of clinical response in two Phase III RCTs: mortality rates for the pooled trials were comparable with telavancin (20%) and vancomycin (18.6%). Pooled data from cSSTIs and HAP studies on telavancin 10 mg/kg indicated higher rates of serum creatinine increases (OR = 2.22 [1.38–3.57]), serious adverse events (OR = 1.53 [1.05–2.24]), and adverse event-related withdrawals (OR = 1.49 [1.14–1.95]) among telavancin recipients. Conclusion : Telavancin might be an alternative to vancomycin in cases of difficult-to-treat MRSA infections. The potent antistaphylococcal activity of telavancin should be weighted against the potential for nephrotoxicity.


Click To View

Additional Books

  • Plos One : Microrna-550A Acts as a Pro-m... (by )
  • Plos One : Overexpression of Mir -155 Pr... (by )
  • Plos One : Imputing Amino Acid Polymorph... (by )
  • Plos One : Lmx1A Encodes a Rostral Set o... (by )
  • Plos One : Crystal Structures of a Plant... (by )
  • Plos One : Epidemiological Analysis of H... (by )
  • Plos One : Pre-treatment Levels of C-rea... (by )
  • Plos One : Molecular Parentage Analysis ... (by )
  • Plos One : Spatial Distribution of Darpp... (by )
  • Plos One : Inhibitory Peptide of Mitocho... (by )
  • Plos One : Characterization of Multisuga... (by )
  • Plos One : Movement Disorders in Elderly... (by )
Scroll Left
Scroll Right


Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.